{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "FlublokPI",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 2
  },
  "completeness_stats": {
    "existing_evidence": 3,
    "new_evidence_found": 2,
    "total_evidence": 5
  },
  "verified_evidence": [
    {
      "id": "comp_1",
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to ece ive Flublok Quad rival ent or Comparator (Fluarix Quad rival ent, manufactured by Glaxo smith kline) as an active control [see Clinical Studies (14 1. The safety analysis opu lati on included 4328 Flublok Quad rival ent recipients and 4344 Comparator vaccine eci pie nts.",
      "supports_claim": true,
      "explanation": "A very similar version of the quote appears on page 3: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to ece ive Flublok Quad rival ent or Comparator (Fluarix Quad rival ent, manufactured by Glaxo smith kline) as an active control [see Clinical Studies (14 1. The safety analysis opu lati on included 4328 Flublok Quad rival ent recipients and 4344 Comparator vaccine eci pie nts.' The wording and numbers match the quote to verify, with only minor spacing and typographical differences due to OCR or formatting.. The quote directly states that Study 6 randomized subjects to receive either Flublok Quadrivalent or Fluarix Quadrivalent (manufactured by GlaxoSmithKline) as an active control. This confirms that Flublok (quadrivalent) was evaluated in a pivotal trial against Fluarix (quadrivalent standard-dose vaccine), thus directly supporting the claim.",
      "presence_explanation": "A very similar version of the quote appears on page 3: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to ece ive Flublok Quad rival ent or Comparator (Fluarix Quad rival ent, manufactured by Glaxo smith kline) as an active control [see Clinical Studies (14 1. The safety analysis opu lati on included 4328 Flublok Quad rival ent recipients and 4344 Comparator vaccine eci pie nts.' The wording and numbers match the quote to verify, with only minor spacing and typographical differences due to OCR or formatting.",
      "support_explanation": "The quote directly states that Study 6 randomized subjects to receive either Flublok Quadrivalent or Fluarix Quadrivalent (manufactured by GlaxoSmithKline) as an active control. This confirms that Flublok (quadrivalent) was evaluated in a pivotal trial against Fluarix (quadrivalent standard-dose vaccine), thus directly supporting the claim.",
      "original_relevance": "This quote explicitly states that Study 6 randomized subjects to receive either Flublok Quadrivalent or Fluarix Quadrivalent (standard-dose vaccine) as an active control, directly supporting the claim."
    },
    {
      "id": "comp_2",
      "quote": "Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quad rival ent or a Comparator in activated influenza vaccine (Fluarix\u00ae Quad rival ent, manufactured by Glaxo smith kline). The safety analysis population included 998 recipients of Flublok Quad rival ent and 332 Comparator vaccine recipients.",
      "supports_claim": true,
      "explanation": "A very similar quote appears on page 3: 'Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quad rival ent or a Comparator in activated influenza vaccine (Fluarix\u00ae Quad rival ent, manufactured by Glaxo smith kline). The safety analysis population included 998 recipients of Flublok Quad rival ent and 332 Comparator vaccine recipients.' The wording and numbers match the quote to verify, with only minor formatting and spacing differences.. The quote directly states that Study 7 enrolled subjects who were randomized to receive either Flublok Quadrivalent or Fluarix Quadrivalent (the comparator), and provides the number of recipients in each group. This directly supports the claim that Flublok (quadrivalent) was evaluated in a pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "A very similar quote appears on page 3: 'Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quad rival ent or a Comparator in activated influenza vaccine (Fluarix\u00ae Quad rival ent, manufactured by Glaxo smith kline). The safety analysis population included 998 recipients of Flublok Quad rival ent and 332 Comparator vaccine recipients.' The wording and numbers match the quote to verify, with only minor formatting and spacing differences.",
      "support_explanation": "The quote directly states that Study 7 enrolled subjects who were randomized to receive either Flublok Quadrivalent or Fluarix Quadrivalent (the comparator), and provides the number of recipients in each group. This directly supports the claim that Flublok (quadrivalent) was evaluated in a pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote shows that in Study 7, Flublok Quadrivalent was evaluated against Fluarix Quadrivalent, further supporting the claim that these two vaccines were compared in pivotal trials."
    },
    {
      "id": "comp_3",
      "quote": "Comparator=U.S.- licensed quad rival ent in activated influenza vaccine, Fluarix quad rival ent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.",
      "supports_claim": true,
      "explanation": "A very similar version of the quote appears on page 4: 'Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.- licensed quad rival ent in activated influenza vaccine, Fluarix quad rival ent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.' The wording and abbreviations match the quote to verify, with only minor formatting and spacing differences.. The quote directly states that the comparator in Study 6 was 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix quadrivalent, manufactured by GlaxoSmithKline.' This confirms that Flublok quadrivalent was evaluated in a pivotal trial (Study 6, NCT02285998) against Fluarix quadrivalent, which is a standard-dose vaccine. Therefore, the quote genuinely supports the claim.",
      "presence_explanation": "A very similar version of the quote appears on page 4: 'Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.- licensed quad rival ent in activated influenza vaccine, Fluarix quad rival ent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.' The wording and abbreviations match the quote to verify, with only minor formatting and spacing differences.",
      "support_explanation": "The quote directly states that the comparator in Study 6 was 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix quadrivalent, manufactured by GlaxoSmithKline.' This confirms that Flublok quadrivalent was evaluated in a pivotal trial (Study 6, NCT02285998) against Fluarix quadrivalent, which is a standard-dose vaccine. Therefore, the quote genuinely supports the claim.",
      "original_relevance": "This quote clarifies that the comparator in Study 6 was Fluarix Quadrivalent, confirming that Flublok Quadrivalent was evaluated against this standard-dose vaccine."
    }
  ],
  "new_evidence": [
    {
      "id": "comp_1",
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 \u2013 [Attack rate Flublok Quad rival ent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).",
      "relevance_explanation": "This quote describes Study 6, identifying Flublok Quadrivalent and a Comparator, and details the calculation of efficacy between these two groups, supporting that Flublok Quadrivalent was evaluated against another vaccine in a pivotal trial.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.- licensed quad rival ent in activated influenza vaccine, Fluarix quad rival ent, manufactured by Glaxo smith kline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.",
      "relevance_explanation": "This quote explicitly defines the Comparator in Study 6 as Fluarix Quadrivalent, confirming that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent in the pivotal trial.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "model_used": "gpt-4.1"
}